DK1276501T5 - Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi - Google Patents

Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Info

Publication number
DK1276501T5
DK1276501T5 DK01928938T DK01928938T DK1276501T5 DK 1276501 T5 DK1276501 T5 DK 1276501T5 DK 01928938 T DK01928938 T DK 01928938T DK 01928938 T DK01928938 T DK 01928938T DK 1276501 T5 DK1276501 T5 DK 1276501T5
Authority
DK
Denmark
Prior art keywords
photodynamic therapy
treating tumors
tumor
bearing
treating
Prior art date
Application number
DK01928938T
Other languages
Danish (da)
English (en)
Other versions
DK1276501T3 (da
Inventor
William C Fanslow Iii
Elaine K Thomas
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DK1276501T3 publication Critical patent/DK1276501T3/da
Application granted granted Critical
Publication of DK1276501T5 publication Critical patent/DK1276501T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01928938T 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi DK1276501T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19954500P 2000-04-25 2000-04-25
PCT/US2001/013616 WO2001080888A2 (fr) 2000-04-25 2001-04-25 Procede de traitement des tumeurs par therapie photodynamique

Publications (2)

Publication Number Publication Date
DK1276501T3 DK1276501T3 (da) 2006-04-24
DK1276501T5 true DK1276501T5 (da) 2007-02-26

Family

ID=22737985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01928938T DK1276501T5 (da) 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Country Status (10)

Country Link
US (2) US20020041864A1 (fr)
EP (1) EP1276501B9 (fr)
AT (1) ATE313334T1 (fr)
AU (2) AU5574001A (fr)
CA (1) CA2407336A1 (fr)
DE (1) DE60116075T4 (fr)
DK (1) DK1276501T5 (fr)
ES (1) ES2254408T4 (fr)
PT (1) PT1276501E (fr)
WO (1) WO2001080888A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1357944B1 (fr) * 2001-01-30 2007-06-13 Altachem Pharma Ltd. Perylenequinones destinees a etre utilisees comment agents immunotherapeutiques
IL157946A0 (en) * 2001-04-02 2004-03-28 Genentech Inc Combination therapy
AU2003226082A1 (en) * 2002-03-25 2003-11-11 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
US8372409B2 (en) * 2003-04-09 2013-02-12 University Of Florida Research Foundation, Inc. Dendritic cell binding proteins and uses thereof
WO2007016762A1 (fr) * 2005-08-10 2007-02-15 Quest Pharmatech Inc. Dérivés de pérylènequinone et leurs utilisations
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
EP2718457A4 (fr) * 2011-06-06 2014-12-24 Immungene Inc Molécules de fusion génétiquement modifiées ligand élément tnfsf-anticorps
EP3973973A1 (fr) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Vecteur de plateforme oncolytique pour administration systémique
WO2020047327A2 (fr) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Protéines chimériques à base de flt3l
JP7612617B2 (ja) * 2019-06-17 2025-01-14 レノヴァロ バイオファーマ インコーポレイテッド 細胞性免疫及び体液性免疫を誘導するための同種異系ｔ細胞ベースのｈｉｖワクチン
CA3197371A1 (fr) 2020-11-19 2022-05-27 Kalivir Immunotherapeutics, Inc. Immunotherapie oncolytique par remodelage d'un micro-environnement tumoral
EP4329786A4 (fr) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Virus oncolytiques d'expression de cmh modifiée
IL309186A (en) * 2021-06-17 2024-02-01 Kalivir Immunotherapeutics Inc TNFSF-L fusion proteins and their uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
DE69334070T2 (de) * 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
EP0751781B1 (fr) * 1993-12-23 2004-05-26 Immunex Corporation Utilisation d'anticorps monoclonaux ou de ligands oligomeriques solubles pour la preparation d'un medicament pour le traitement de maladies neoplasiques
US6495129B1 (en) * 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
CA2232865A1 (fr) * 1995-10-04 1997-04-10 Immunex Corporation Facteur de stimulation flt3 de cellules dendritiques
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US6146409A (en) * 1996-05-20 2000-11-14 Bergein F. Overholt Therapeutic methods and devices for irradiating columnar environments
NZ333607A (en) * 1996-07-10 2000-08-25 Immunex Corp Method of stimulating the immune system by transfecting dendritic cells
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
AU2789900A (en) * 1999-02-26 2000-09-21 Qlt Phototherapeutics, Inc. Photodynamic therapy in combination with apoptosis inducing factors
US6756141B2 (en) * 2001-04-17 2004-06-29 Southwest Research Institute Three-electrode fuel cell

Also Published As

Publication number Publication date
DE60116075T4 (de) 2007-06-06
CA2407336A1 (fr) 2001-11-01
ES2254408T4 (es) 2007-10-01
EP1276501A2 (fr) 2003-01-22
ES2254408T3 (es) 2006-06-16
DK1276501T3 (da) 2006-04-24
AU2001255740B2 (en) 2006-03-16
DE60116075T2 (de) 2006-08-31
US20050129689A1 (en) 2005-06-16
DE60116075D1 (de) 2006-01-26
WO2001080888A2 (fr) 2001-11-01
WO2001080888A3 (fr) 2002-08-29
EP1276501B1 (fr) 2005-12-21
EP1276501B9 (fr) 2007-01-24
PT1276501E (pt) 2006-05-31
US20020041864A1 (en) 2002-04-11
ATE313334T1 (de) 2006-01-15
AU5574001A (en) 2001-11-07

Similar Documents

Publication Publication Date Title
DK1276501T3 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
NO20022065D0 (no) Terapeutisk anvendelse
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
WO2002066044A3 (fr) Procede de traitement de tumeurs utilisant une polytherapie
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2001082961A3 (fr) Procedes de traitement des tumeurs osseuses
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
NO20072543L (no) Anti-cancer-behandling
WO2005092073A3 (fr) Utilisation d'anticorps anti-$g(a)5$g(b)1 pour inhiber la proliferation des cellules cancereuses
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2001007028A3 (fr) Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2000057911A3 (fr) Cellules mammaliennes conjuguees a un haptene, et methodes de preparation et d'utilisation correspondantes
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
WO2005041860A3 (fr) Cellules souches utilisees pour localiser et cibler des cellules tumorales
TW200724158A (en) Combination therapy in the treatment of cancer
BR0308976A (pt) Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
WO2005006947A3 (fr) Cellules utilisees pour localiser et cibler des cellules tumorales
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей
WO2003059334A3 (fr) Gemcitabine pour traiter la variole